# A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

> **NCT02145026** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 100 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Epoetin beta

## Key facts

- **NCT ID:** NCT02145026
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-06
- **Primary completion:** 2019-04-09
- **Final completion:** 2019-04-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145026, "A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02145026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*